Citi analyst Joel Beatty says The Medicines Co. will likely become a takeover target if its Phase 3 data in Q3 shows "clean safety." The years of accumulated safety data supports that "clean" Phase 3 results are likely, Beatty tells investors in a research note. The analyst keeps a Buy rating on the shares with a $50 price target. He also believes Medicines' $173M debt offering likely reflects the increased risk around the Melinta infectious disease partnership. Medicines' annual filing indicates that Melinta is seeking indemnification to not pay the two $25M deferred payments or the $30M Vabomere milestone payment due to its former owners, says the analyst. If not paid the milestone responsibility falls back onto The Medicines Co., Beatty notes.